RenovoRx, Inc.: director Macfarlane K. Angela received 55,924 shares

What happened

• Macfarlane K. Angela, director, received 55,924 derivative shares as an award. The filing reports an acquisition price of $0.00 per share and a total value of $0. The transaction is reported as a grant/award (code A).

Key details

• Transaction date: Oct 1, 2026. Filing date: Oct 2, 2026.
• Shares acquired: 55,924. Price per share: $0.00. Total value reported: $0.
• Shares owned after the transaction: not reported in the filing.
• Footnote F1: the shares subject to the option vest in 12 equal monthly installments beginning on Nov 1, 2026.
• Filing timeliness: the filing does not indicate that it was late.

Why it may matter

• This was a derivative award subject to vesting, not a market trade or sale.
• This filing does not show why the insider traded or why the company acted.